TY - JOUR
T1 - Treatment of acute diverticulitis laparoscopic lavage vs. resection (DILALA)
T2 - study protocol for a randomised controlled trial
AU - Thornell, Anders
AU - Angenete, Eva
AU - Gonzales, Elisabeth
AU - Heath, Jane
AU - Jess, Per
AU - Läckberg, Zoltan
AU - Ovesen, Henrik
AU - Rosenberg, Jacob
AU - Skullman, Stefan
AU - Haglind, Eva
AU - Ssorg, Scandinavian Surgical Outcome Research Group
AU - Thornell, Anders
AU - Angenete, Eva
AU - Gonzales, Elisabeth
AU - Heath, Jane
AU - Jess, Per
AU - Läckberg, Zoltan
AU - Ovesen, Henrik
AU - Rosenberg, Jacob
AU - Skullman, Stefan
AU - Haglind, Eva
AU - Scandinavian Surgical Outcomes Research Group, SSORG
PY - 2011/8/1
Y1 - 2011/8/1
N2 - Perforated diverticulitis is a condition associated with substantial morbidity. Recently published reports suggest that laparoscopic lavage has fewer complications and shorter hospital stay. So far no randomised study has published any results.Methods: DILALA is a Scandinavian, randomised trial, comparing laparoscopic lavage (LL) to the traditional Hartmann's Procedure (HP). Primary endpoint is the number of re-operations within 12 months. Secondary endpoints consist of mortality, quality of life (QoL), re-admission, health economy assessment and permanent stoma. Patients are included when surgery is required. A laparoscopy is performed and if Hinchey grade III is diagnosed the patient is included and randomised 1:1, to either LL or HP. Patients undergoing LL receive > 3L of saline intraperitoneally, placement of pelvic drain and continued antibiotics. Follow-up is scheduled 6-12 weeks, 6 months and 12 months. A QoL-form is filled out on discharge, 6- and 12 months. Inclusion is set to 80 patients (40+40).Discussion: HP is associated with a high rate of complication. Not only does the primary operation entail complications, but also subsequent surgery is associated with a high morbidity. Thus the combined risk of treatment for the patient is high. The aim of the DILALA trial is to evaluate if laparoscopic lavage is a safe, minimally invasive method for patients with perforated diverticulitis Hinchey grade III, resulting in fewer re-operations, decreased morbidity, mortality, costs and increased quality of life.Trial registration: British registry (ISRCTN) for clinical trials ISRCTN82208287http://www.controlled-trials.com/ISRCTN82208287.
AB - Perforated diverticulitis is a condition associated with substantial morbidity. Recently published reports suggest that laparoscopic lavage has fewer complications and shorter hospital stay. So far no randomised study has published any results.Methods: DILALA is a Scandinavian, randomised trial, comparing laparoscopic lavage (LL) to the traditional Hartmann's Procedure (HP). Primary endpoint is the number of re-operations within 12 months. Secondary endpoints consist of mortality, quality of life (QoL), re-admission, health economy assessment and permanent stoma. Patients are included when surgery is required. A laparoscopy is performed and if Hinchey grade III is diagnosed the patient is included and randomised 1:1, to either LL or HP. Patients undergoing LL receive > 3L of saline intraperitoneally, placement of pelvic drain and continued antibiotics. Follow-up is scheduled 6-12 weeks, 6 months and 12 months. A QoL-form is filled out on discharge, 6- and 12 months. Inclusion is set to 80 patients (40+40).Discussion: HP is associated with a high rate of complication. Not only does the primary operation entail complications, but also subsequent surgery is associated with a high morbidity. Thus the combined risk of treatment for the patient is high. The aim of the DILALA trial is to evaluate if laparoscopic lavage is a safe, minimally invasive method for patients with perforated diverticulitis Hinchey grade III, resulting in fewer re-operations, decreased morbidity, mortality, costs and increased quality of life.Trial registration: British registry (ISRCTN) for clinical trials ISRCTN82208287http://www.controlled-trials.com/ISRCTN82208287.
U2 - 10.1186/1745-6215-12-186
DO - 10.1186/1745-6215-12-186
M3 - Journal article
C2 - 21806795
SN - 1745-6215
VL - 12
SP - 186
EP - 190
JO - Trials
JF - Trials
ER -